PT-141

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide composed of seven amino acids, developed as a structural analog (also spelled analog) of alpha-melanocyte-stimulating hormone (alpha-MSH), a naturally occurring neuropeptide produced in the pituitary gland that regulates pigmentation, appetite, energy balance, and sexual behavior. ^(1,2) The peptide’s generic name is bremelanotide, and its FDA-approved pharmaceutical form is marketed as Vyleesi. ^(2,4)

The origin of PT-141 traces back to melanocortin research at the University of Arizona in the 1990s. Scientists investigating Melanotan II, a synthetic alpha-MSH analog developed for sunless tanning, observed unexpected and pronounced sexual arousal effects during early clinical testing. ^(1,3) This serendipitous discovery redirected research toward the melanocortin system’s role in sexual function, leading to the development of PT-141 as a more selective compound. PT-141 is essentially a cyclized (also spelled cyclized) lactam analog of Melanotan II, structurally refined to preserve the receptor-binding properties relevant to sexual function while reducing the pigmentation effects that dominated the parent compound. ^(1,3)

PT-141 acts by selectively activating melanocortin-3 and melanocortin-4 receptors (MC3R and MC4R) in hypothalamic and limbic brain regions that govern sexual motivation, arousal, and reward. ^(1,2) This central nervous system mechanism fundamentally distinguishes PT-141 from all other sexual function compounds: PDE5 inhibitors like sildenafil (Viagra) and tadalafil (Cialis) work peripherally by increasing blood flow to genital tissue, addressing the physical mechanics of sexual response. PT-141 works centrally in the brain, influencing sexual desire itself. ^(1,2) This distinction is critical for researchers and is reflected in the clinical data showing efficacy in populations that do not respond to PDE5 inhibitors.

In June 2019, the FDA approved bremelanotide (Vyleesi) for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, making it the first FDA-approved as-needed treatment specifically targeting the neurological basis of sexual desire. ^(2,4) The approval was supported by two Phase III clinical trials (RECONNECT studies) enrolling over 1,200 women. ⁽⁴⁾ The approved Vyleesi formulation uses a subcutaneous auto-injector device administered approximately 45 minutes before anticipated sexual activity, with a maximum of one dose per 24 hours and eight doses per month. ⁽⁴⁾

PT-141 is not FDA approved for use in men, for postmenopausal women, or for any indication other than premenopausal HSDD. ⁽⁴⁾ Male erectile dysfunction research with bremelanotide has progressed through Phase II trials but has not achieved separate FDA approval. ^(5,6) PT-141 is not currently classified as a controlled substance. It is not explicitly listed on the WADA Prohibited List, though researchers subject to anti-doping testing should independently verify their current status. ⁽⁷⁾ Healius supplies PT-141 as a lyophilized (also referred to as lyophilized) powder in 10mg vials, intended strictly for laboratory and research applications.

PT-141’s mechanism of action operates through a fundamentally different pathway than any other sexual function compound on the market or in research. ^(1,2)

The peptide selectively binds to and activates melanocortin-4 receptors (MC4R) and exhibits secondary activity at MC3R in brain regions central to sexual behavior. ^(1,2) MC4R receptors are densely expressed in the hypothalamus (particularly the paraventricular nucleus and medial preoptic area), the limbic system, and other CNS regions involved in motivation, reward, and arousal. ^(1,2) When PT-141 binds to these receptors, it activates adenylyl cyclase and cyclic adenosine monophosphate (cAMP) signaling pathways, enhancing neuronal excitability in sexual behavior control centers. ⁽¹⁾

The downstream neurochemical effects include stimulation of dopamine and oxytocin release in reward pathways, modulation of hypothalamic-pituitary-gonadal axis activity, and activation of descending neural pathways to sexual response centers. ^(1,2) Dopamine is the primary neurotransmitter associated with desire, motivation, and reward-seeking behavior, while oxytocin is involved in bonding, arousal, and orgasm. By engaging both systems, PT-141 influences multiple phases of the sexual response cycle: desire, arousal, and satisfaction. ⁽¹⁾

This central mechanism explains why PT-141 can be effective in individuals who do not respond to PDE5 inhibitors. A man who can achieve adequate blood flow but lacks desire, or whose erectile dysfunction has a neurological or psychological component, represents the target population for a centrally acting compound. ^(5,6) Similarly, HSDD in women is primarily a disorder of desire, not of genital vascular response, which is why a brain-targeted approach achieved FDA approval where vascular agents had not. ⁽⁴⁾

PT-141 does not directly affect testosterone levels, though the question is frequently searched. The melanocortin system interacts with the HPG axis, and some research suggests indirect modulatory effects on gonadotropin release, but PT-141 is not a testosterone booster and should not be framed as one. ^(1,2) Its effects on sexual function are mediated through desire and arousal pathways, not through androgen modulation.

The clinical evidence base for PT-141 in women is the most robust among research peptides, having achieved the gold standard of two successful Phase III trials that led to FDA approval. ⁽⁴⁾

The RECONNECT studies enrolled over 1,200 premenopausal women diagnosed with acquired, generalized HSDD. ⁽⁴⁾ HSDD is characterized (also spelled characterized) by persistent low sexual desire that causes marked personal distress or interpersonal difficulty, not attributable to other medical conditions, psychiatric disorders, relationship problems, or medication side effects. ⁽⁴⁾ The studies demonstrated statistically significant improvements in sexual desire (measured by the Female Sexual Distress Scale-Desire/Arousal/Orgasm) and reductions in distress associated with low sexual desire compared to placebo. ⁽⁴⁾

The approved Vyleesi dose is 1.75 mg administered subcutaneously via auto-injector approximately 45 minutes before anticipated sexual activity. ⁽⁴⁾ Effects typically onset within 30-60 minutes and can last 6-12 hours based on clinical observations. ^(2,4) The prescribing information limits use to one dose per 24 hours and a maximum of eight doses per month, reflecting the potential for melanocortin receptor desensitization (also spelled desensitization) with more frequent dosing. ⁽⁴⁾

PT-141 is not approved for postmenopausal women. The Phase III trials specifically enrolled premenopausal women, and the FDA label is limited to this population. ⁽⁴⁾ Research into postmenopausal HSDD continues, but separate regulatory approval would be required for label expansion. Similarly, PT-141 is not indicated for general sexual performance enhancement or for women without a clinical HSDD diagnosis.

The approval of Vyleesi in 2019 was significant because it represented the first on-demand, non-hormonal treatment for HSDD. The only other FDA-approved HSDD treatment, flibanserin (Addyi), requires daily dosing, has significant drug-alcohol interactions, and works through serotonin receptor modulation rather than melanocortin pathways. ⁽⁴⁾ PT-141’s on-demand dosing, distinct mechanism, and rapid onset positioned it as a meaningfully different therapeutic option.

PT-141 has been investigated in multiple clinical studies for male erectile dysfunction, with results demonstrating efficacy through a mechanism distinct from existing ED treatments. ^(5,6)

An early randomized controlled trial examining bremelanotide in men with ED reported that 67% of PT-141 recipients showed improved erections compared to 33% receiving placebo (p < 0.01), with sustained improvement throughout an 8-week treatment period. ⁽⁵⁾ A separate study by Safarinejad and Hosseini ⁽²⁰⁰⁸⁾ examined PT-141 in 180 men with sildenafil-resistant ED using a crossover design and reported 62% improvement in the PT-141 group versus 21% with placebo (p < 0.001). ⁽⁶⁾ This finding in PDE5 inhibitor non-responders is particularly significant, as it demonstrates efficacy in a population with limited treatment options.

Phase IIB trials examining bremelanotide over three months in patients with diabetes-induced ED reported significant increases in the International Index of Erectile Function (IIEF) scores, offering data for men whose diabetes has affected their sexual health. ⁽⁵⁾ Research has also demonstrated that co-administration of PT-141 (7.5 mg) with sildenafil (25 mg) produced an erectile response significantly greater than sildenafil alone, suggesting a synergistic relationship between central and peripheral mechanisms. ⁽⁵⁾

In 2024, Palatin Technologies announced the initiation of a Phase II clinical study of bremelanotide co-administered with a PDE5 inhibitor for the treatment of erectile dysfunction, signaling renewed commercial interest in the male indication. ⁽⁸⁾ A 2024 case series from a sexual medicine clinic reported on the use of Vyleesi in men with sexual dysfunctions, providing additional real-world clinical data. ⁽⁸⁾

Despite this clinical data, PT-141 has not achieved FDA approval for male ED. The male studies, while positive, are smaller in scale than the female HSDD Phase III program and do not meet the evidentiary threshold for a separate New Drug Application. ^(5,6) Male use of bremelanotide remains off-label.

The comparison between PT-141 and PDE5 inhibitors (sildenafil/Viagra, tadalafil/Cialis) is one of the most frequently searched topics in sexual function research, and understanding the distinction is essential for protocol design. ^(1,2)

PDE5 inhibitors act peripherally by blocking phosphodiesterase type 5 in penile smooth muscle, increasing cyclic GMP levels, and enhancing blood flow to erectile tissue in response to sexual stimulation. ⁽¹⁾ They are effective mechanical facilitators: they create the vascular conditions for an erection but do not generate desire, arousal, or motivation. A man with no libido but functional vasculature will experience limited benefit from a PDE5 inhibitor alone. ⁽¹⁾

PT-141 acts centrally by activating MC3R/MC4R receptors in the brain’s sexual behavior centers, enhancing dopamine and oxytocin release in desire and reward pathways. ^(1,2) It influences the psychological and motivational signal itself rather than the downstream vascular response. PT-141 is more accurately described as a desire enhancer than a performance enhancer. ⁽¹⁾

In practical research terms, the two approaches are complementary rather than competitive. PT-141 addresses the central desire component; PDE5 inhibitors address the peripheral vascular component. Clinical data showing enhanced responses when PT-141 is co-administered with sildenafil support the synergistic model: targeting both the brain (desire) and the vasculature (mechanics) simultaneously produces greater effects than either approach alone. ⁽⁵⁾

PT-141 also differs from PDE5 inhibitors in its applicability to women. PDE5 inhibitors have consistently failed to demonstrate meaningful efficacy for female sexual dysfunction because the primary issue in HSDD is desire, not genital blood flow. ⁽⁴⁾ PT-141’s central mechanism addressed this gap, which is why it, not a vascular agent, achieved FDA approval for female HSDD.

Melanotan 2 (MT2) is PT-141’s parent compound, and understanding the relationship between them is important for researchers working with melanocortin peptides. ^(1,3)

Melanotan II is a synthetic cyclic heptapeptide analog of alpha-MSH with broad melanocortin receptor activity. It activates MC1R (pigmentation), MC3R and MC4R (sexual function, energy balance), and MC5R (sebaceous gland function). ⁽³⁾ This broad receptor profile produces a range of effects, including skin tanning, appetite suppression, and sexual arousal. The sexual arousal effects observed during Melanotan II clinical trials were the catalyst for developing PT-141. ^(1,3)

PT-141 was engineered from Melanotan II to be more selective for the MC3R/MC4R subtypes involved in sexual function while reducing activity at MC1R (the pigmentation receptor). ^(1,3) The structural difference is that PT-141 is a cyclic lactam analog that lacks the linear tail responsible for much of Melanotan II’s tanning activity. This selectivity shift means PT-141 produces more targeted effects on sexual function, with less pigmentation as a side effect, though some residual tanning can still occur. ^(1,3)

For researchers, the key distinction is that Melanotan II is a broader melanocortin agonist studied for its effects on pigmentation, appetite, and sexual function across multiple receptor subtypes. PT-141 is a more selective melanocortin agonist focused specifically on the CNS pathways governing sexual desire and arousal. PT-141 has the stronger clinical evidence base for sexual function (FDA approval), while Melanotan II has the broader pharmacological profile but has not achieved regulatory approval for any indication. ⁽³⁾

1. PT-141 (Bremelanotide): Synthetic cyclic heptapeptide, alpha-MSH analog, selective MC3R/MC4R agonist. Central CNS mechanism distinct from PDE5 inhibitors. Derived from Melanotan II research at the University of Arizona. Multiple clinical pharmacology reviews.

2. PeptideBreakdown. PT-141 (Bremelanotide): Research, Mechanism, and Clinical Evidence for Sexual Function. Updated February 2026. Comprehensive evidence-based review.

3. Melanotan II relationship: PT-141 is a cyclic lactam analog of Melanotan II, refined to reduce MC1R (pigmentation) activity while preserving MC3R/MC4R (sexual function) selectivity: Molinoff et al., Annals of the New York Academy of Sciences, 2003.

4. FDA. Vyleesi (bremelanotide injection) Prescribing Information. Approved June 21, 2019. Indication: acquired, generalized HSDD in premenopausal women. Phase III RECONNECT studies, 1,200+ women. Dose: 1.75 mg SubQ. Max 1 dose/24hr, 8 doses/month.

5. Multiple Phase II clinical trials in male ED: 67% improved erections vs 33% placebo; Phase IIB in diabetes-induced ED with significant IIEF improvements; PT-141 (7.5 mg) + sildenafil (25 mg) synergy data. Wessells et al., Ann N Y Acad Sci, 2000; Diamond et al., J Sex Med, 2006.

6. Safarinejad MR, Hosseini SY. Bremelanotide in sildenafil-resistant erectile dysfunction. 180 men, crossover design. 62% improvement vs 21% placebo (p < 0.001). 2008.

7. WADA Prohibited List 2026. PT-141/bremelanotide is not explicitly listed by compound name. Vyleesi is FDA-approved (S0 catch-all does not apply to approved pharmaceuticals).

8. Palatin Technologies (2024). Phase II study initiation: bremelanotide co-administered with a PDE5 inhibitor for ED. Press release. Also: Use of Bremelanotide (Vyleesi) in Men with Sexual Dysfunctions: Results from a Sexual Medicine Clinic. J Sex Med, 2024.

9. Kisspeptin/GPR54 signaling pathway: distinct from the melanocortin system. Kisspeptin activates GnRH neurons, stimulating the release of LH and FSH. Complementary to PT-141’s direct desire pathway modulation.

10. Kingsberg SA, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women: two randomized clinical trials. Obstetrics & Gynecology. 2019.

11. Clayton AH, et al. Efficacy and safety of bremelanotide for HSDD: clinical trial results. Journal of Sexual Medicine. 2016.

12. Shadiack AM, et al. Melanocortins in sexual function: emerging science and therapeutic opportunities. Peptides. 2007.

13. Bruce R. Gilbert, MD, PhD. PT-141 for Men: A New Drug to Treat Erectile Dysfunction and Low Libido. MensReproductiveHealth.com. 2025. Clinical review of male bremelanotide data, off-label use, regulatory status, and combination strategies.

14. Tower Urology. PT-141 Peptide Therapy: Clinical overview including Phase IIB diabetes-ED data, sildenafil co-administration results, and cardiovascular safety profile. 2025.

This product is sold strictly for laboratory and research use only. It is not intended for human or animal consumption. It is not a dietary supplement, food, drug, or cosmetic. It is not intended to diagnose, treat, cure, or prevent any disease or condition. The buyer assumes all responsibility for the lawful use of this product in accordance with all applicable local, state, national, and international laws and regulations. By purchasing this product, the buyer confirms that they are a qualified researcher or are purchasing on behalf of a research institution.